Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 3/20 | 0.31 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8497383 | 0.80 | CPB2 (0.36) | GSRCPB2GABRR1ASAH1DPP4 | |
| SCHEMBL482961 | 0.78 | CPB2 (0.44) | GSRCPB2GABRR1SLC7A5RNPEP | |
| SCHEMBL482963 | 0.78 | CPB2 (0.44) | GSRCPB2GABRR1SLC7A5RNPEP | |
| SCHEMBL7271506 | 0.72 | GSR (0.50) | GSRCPB2GABRR1SLC7A5RNPEP | |
| SCHEMBL5280980 | 0.72 | GSR (0.50) | GSRCPB2GABRR1SLC7A5RNPEP | |
| SCHEMBL15771643 | 0.71 | FOLH1 (0.49) | CPB2SLC6A5FOLH1 | |
| SCHEMBL28011992 | 0.71 | GSR (0.45) | GSRCPB2GABRR1SLC7A5RNPEP | |
| SCHEMBL3864466 | 0.70 | SMN1; SMN2 (0.46) | SLC6A5FAAHASAH1SMN1; SMN2 | |
| SCHEMBL30628732 | 0.70 | SMN1; SMN2 (0.46) | SLC6A5FAAHASAH1SMN1; SMN2 | |
| SCHEMBL6954452 | 0.70 | SMN1; SMN2 (0.46) | SLC6A5FAAHASAH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0590038-B1 | AMINO ACID DERIVATIVE AND BROMOACETYL MODIFIED PEPTIDES | US HEALTH (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0590038-A1 | AMINO ACID DERIVATIVE AND BROMOACETYL MODIFIED PEPTIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-04-06 | — | — | EP | claimed |
| US-9629934-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | DYAX CORP. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9446155-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE SA (CH) | 2016-09-20 | — | — | US | disclosed |
| US-9408926-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE S.A. (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2015-12-31 | — | — | US | disclosed |
| US-9056138-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2015-06-16 | — | — | US | disclosed |
| EP-2111237-B1 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING SPA (IT) | 2015-03-18 | — | — | EP | disclosed |
| US-20140286864-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE SA (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | DYAX CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140161732-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE S.A. (CH) | 2014-06-12 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| WO-2004065621-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2004-01-29 | — | — | US | disclosed |
| WO-2003084574-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL BV (NL) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003074005-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-0740792-B1 | PEPTOMERS WITH ENHANCED IMMUNOGENICITY | US HEALTH (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0590038-B1 | AMINO ACID DERIVATIVE AND BROMOACETYL MODIFIED PEPTIDES | US HEALTH (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0590038-A1 | AMINO ACID DERIVATIVE AND BROMOACETYL MODIFIED PEPTIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5286846-A | Trifunctional reagents for solid phase synthesis | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT. OF HEALTH AND HUMAN SERVICES (US) | 1994-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | GSR 2963/4885CPB2 1624/4885GABRR1 3089/4885 |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | GSR 2963/4885CPB2 1624/4885GABRR1 3089/4885 |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | CD47, BCR, CD44 | GSR 2963/4885CPB2 1624/4885GABRR1 3089/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | GSR 3935/4885CPB2 1328/4885GABRR1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.